Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 2
2018 1
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
Meßner M, Schmitt S, Ardelt MA, Fröhlich T, Müller M, Pein H, Huber-Cantonati P, Ortler C, Koenig LM, Zobel L, Koeberle A, Arnold GJ, Rothenfußer S, Kiemer AK, Gerbes AL, Zischka H, Vollmar AM, Pachmayr J. Meßner M, et al. Among authors: ardelt ma. FASEB J. 2020 Sep;34(9):11860-11882. doi: 10.1096/fj.202001128R. Epub 2020 Jul 11. FASEB J. 2020. PMID: 32652772
Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.
Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J. Ardelt MA, et al. Hepatology. 2019 Jan;69(1):376-393. doi: 10.1002/hep.30190. Epub 2018 Dec 22. Hepatology. 2019. PMID: 30033593 Free PMC article.
Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT.
Merk H, Messer P, Ardelt MA, Lamb DC, Zahler S, Müller R, Vollmar AM, Pachmayr J. Merk H, et al. Among authors: ardelt ma. Mol Cancer Ther. 2017 Nov;16(11):2329-2339. doi: 10.1158/1535-7163.MCT-17-0129. Epub 2017 Aug 3. Mol Cancer Ther. 2017. PMID: 28775146 Free article.